News & Events about Genmab A S.
Company Announcement COPENHAGEN, Denmark; January 19, 2023 Genmab A/S (Nasdaq: GMAB) Correction: In company announcement no. 1/2023regarding transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons it was reported thatmember of ...
Company Announcement COPENHAGEN, Denmark; January 3, 2023 Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial...
Media ReleaseCOPENHAGEN, Denmark; January 2, 2023Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 41stAnnual J.P. Morgan Healthcare Conference in San Francisco at 9:00 AM PST / 12:00 PM EST / 6:00 PM CET on January 11, 2023.The ...
Media Release COPENHAGEN, Denmark; December 21, 2022 JNDA submission supported by results of Japanese and global phase 2 clinical trials evaluating epcoritamab in patients with mature B-cell non-Hodgkins lymphoma (NHL), including relapsed/refractory large B-cell lymphoma (LBCL) Genmab A/S (Nasdaq: ...
Genmab A/S (Nasdaq: GMAB): JNDA submission supported by results of Japanese and global phase 2 clinical trials evaluating epcoritamab in patients with mature B-cell non-Hodgkins lymphoma (NHL), including relapsed/refractory large B-cell lymphoma (LBCL) Genmab A/S (Nasdaq: GMAB) today announced that...